QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
AstraZeneca, Sinopharm and Moderna were part of the study
It is part of the company’s pain/analgesics portfolio of OTC products
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
It works as an adjunct to standard care based on robust clinical trials
India business is growing as per projections; whereas US business will bounce back soon.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Subscribe To Our Newsletter & Stay Updated
